#### UNITED THERAPEUTICS Corp

Form 4 April 16, 2015

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. See Instruction

30(h) of the Investment Company Act of 1940 1(b).

(Middle)

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* ROTHBLATT MARTINE A

2. Issuer Name and Ticker or Trading

Symbol

UNITED THERAPEUTICS Corp [UTHR]

\_X\_ Director

10% Owner Other (specify X\_ Officer (give title

C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET

(First)

(Street)

04/15/2015

(Month/Day/Year) below)

Chairman & Co-CEO

4. If Amendment, Date Original

3. Date of Earliest Transaction

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

Issuer

#### SILVER SPRING, MD 20910

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ar) Execution Date, if Transa any Code (Month/Day/Year) (Instr.		(A) or			5. Amount of Securities Ownership Beneficially Form: Owned Direct (D) Following or Indirect Reported (I) Transaction(s) (Instr. 4) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	04/15/2015		Code V $M_{\underline{(1)}}$	Amount 2,211	(D)	Price \$ 63.22	2,451	D		
Common Stock	04/15/2015		S(1)	300	D	\$ 184.6267 (2)	2,151	D		
Common Stock	04/15/2015		S(1)	1,400	D	\$ 185.5204 (3)	751	D		
Common	04/15/2015		S(1)	511	D	\$ 186.76	240	D		

## Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

Stock					<u>(4)</u>			
Common Stock	04/16/2015	M(1)	4,115	A	\$ 34.56 (5)	4,355	D	
Common Stock	04/16/2015	S <u>(1)</u>	4,115	D	\$ 186.3921 <u>(6)</u>	240	D	
Common Stock	04/16/2015	M(1)	5,547	A	\$ 30.75 (5)	5,787	D	
Common Stock	04/16/2015	S <u>(1)</u>	700	D	\$ 186.2914 <u>(7)</u>	5,087	D	
Common Stock	04/16/2015	S <u>(1)</u>	1,100	D	\$ 186.99 (8)	3,987	D	
Common Stock	04/16/2015	S <u>(1)</u>	2,219	D	\$ 188.1967 (9)	1,768	D	
Common Stock	04/16/2015	S <u>(1)</u>	1,228	D	\$ 189.0691 (10)	540	D	
Common Stock	04/16/2015	S <u>(1)</u>	300	D	\$ 189.9 (11)	240	D	
Common Stock						166	I	By Spouse
Common Stock						579,065.05	I	By Trusts

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8		5. Num omf Der Securio Acquin (A) or Dispos (D) (Instr. and 5)	ivative ties red sed of 3, 4,	6. Date Exerci Expiration Dat (Month/Day/Y	te	7. Title and A Underlying S (Instr. 3 and	Securities	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number	

SEC 1474

(9-02)

								of Shares
Stock Options	\$ 63.22	04/15/2015	M <u>(1)</u>	2,211	12/31/2010	12/31/2020	Common Stock	2,211
Stock Options	\$ 34.56 (5)	04/16/2015	M <u>(1)</u>	4,115	12/30/2005	12/30/2015	Common Stock	4,115
Stock Options	\$ 30.75 (5)	04/16/2015	M <u>(1)</u>	5,547	12/26/2009	12/31/2017	Common Stock	5,547

Relationshins

# **Reporting Owners**

Reporting Owner Name / Address		110.110.110.110.11p					
	Director	10% Owner	Officer	Other			
ROTHBLATT MARTINE A C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING, MD 20910	X		Chairman & Co-CEO				

## **Signatures**

/s/ John S. Hess, Jr. under Power of Attorney 04/16/2015

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- This transaction was executed in multiple trades at prices ranging from \$183.99 to \$184.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$185.08 to \$186.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$186.41 to \$187.035. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (5) Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- This transaction was executed in multiple trades at prices ranging from \$186.22 to \$186.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$185.59 to \$186.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$186.65 to \$187.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Reporting Owners 3

### Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

- This transaction was executed in multiple trades at prices ranging from \$187.70 to \$188.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$188.70 to \$189.58. The price reported above reflects the (10) weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$189.87 to \$189.93. The price reported above reflects the (11) weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.